GSK Seeks Regulatory Advice To Strategise Drug Development

New GlaxoSmithKline (GSK) CEO Andrew Witty has reaffirmed the company's commitment to developing innovative therapies, and dispelled rumours that a foray into the generics industry may be part of company strategy. Speaking in an interview with the Wall Street Journal, Witty called the generics market a 'tough world to play in', and said that the company had 'far better ways of creating

To read the full article, please choose one of the following options: